ABSTRACT:
A simple, sensitive, accurate, rapid and economical UV-Visible Spectrophotometric method was developed for estimation of Tovorafenib in pure drug and tablet dosage form. The absorbance was measured at 260.2nm using Dimethylsulfoxide as solvent system. It obeyed Beer’s law at the concentration range of 2-14µg/ml with coefficient of correlation (r2) of 0.998. Limit of detection (LOD) was found to be 1.226µg/ml and Limit of quantitation (LOQ) was found to be 5.226µg/ml. The proposed analytical method was validated according to ICH guidelines, yielded good results concerning range, linearity, precision, accuracy, robustness and ruggedness.
Cite this article:
Mohammed Yakhoob, Husnain Fathima, Mohamed Khaleel. Estimation of Tovorafenib Dosage Form and in Bulk Drug by UV Visible Spectrophotometric Method. Asian Journal of Pharmaceutical Analysis. 2025;15(1):20-4. doi: 10.52711/2231-5675.2025.00004
Cite(Electronic):
Mohammed Yakhoob, Husnain Fathima, Mohamed Khaleel. Estimation of Tovorafenib Dosage Form and in Bulk Drug by UV Visible Spectrophotometric Method. Asian Journal of Pharmaceutical Analysis. 2025;15(1):20-4. doi: 10.52711/2231-5675.2025.00004 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-1-4
REFERENCES:
1. Ojemda- tovorafenib kit; Ojemda- tovorafenib tablet, film coated. Daily Med. 26 April 2024. Retrieved 14 May 2024
2. FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma. U.S. Food and Drug Administration (FDA). 23 April 2024. Archived from the original on 23 April 2024. Retrieved 25 April 2024. Public Domain This article incorporates text from this source, which is in the public domain.
3. Novel Drug Approvals for 2024. U.S. Food and Drug Administration (FDA). 29 April 2024. Archived from the original on 30 April 2024. Retrieved 30 April 2024.
4. Day One's Ojemda (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor. Day One Biopharmaceuticals (Press release). 23 April 2024. Archived from the original on 23 April 2024. Retrieved 24 April 2024.
5. World Health Organization (2022). International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88. WHO Drug Information. 36 (3). hdl:10665/363551erendia APMDS. Therapeutic Goods Administration (TGA). 9 December 2021. Retrieved 12 June 2022.
6. Tkacik E, Li K, Gonzalez-Del Pino G, Ha BH, Vinals J, Park E, Beyett TS, Eck MJ: Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. J Biol Chem. 2023 May; 299(5):104634. doi: 10.1016/j.jbc.2023.104634. Epub 2023 Mar 22. [Article]
7. FDA Approved Drug Products: OJEMDA (tovorafenib) suspension and tablets, for oral use
8. https://www.selleckchem.com/products/mln2480.html#:~:text=Chemical%20Information%20%26%20Solubility&text=DMSO%20%3A%20100%20mg%2FmL%20(, Moisture%2Dabsorbing%20DMSO%20reduces%20solubility.
9. Tkacik E, Li K, Gonzalez-Del Pino G, Ha BH, Vinals J, Park E, Beyett TS, Eck MJ: Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. J Biol Chem. 2023 May; 299(5): 104634. doi: 10.1016/j.jbc.2023.104634. Epub 2023 Mar 22
10. Rasco W D, Medina T, Corrie P, C Anna, Pavlick, R Mark, Middleton, Lorigan P, Hebert C, Plummer R, Larkin J, S Sanjiv, Agarwala, I Adil, Daud, Qiu J, Bozon V, Kneissl M, Barry E, J Anthony, Olszanski, Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma, Cancer Chemother Pharmacol. 2023; 92(1):15–28
11. FDA Approves Drug for Chronic Kidney Disease. U.S. Food and Drug Administration (FDA). 9 July 2021. Retrieved 9 July 2021. Public Domain This article incorporates text from this source, which is in the public domain.
12. MarellaLV, Syed Aisha, Prasanna M L and Nalluri N B. A novel validated RP- HPLC method for the estimation of Canagliflozin in bulk and pharmaceutical dosage forms International Journal Research n Pharmaceutical Chemistry 2017; 07(03):24-27
13. Pawar J, Sonawane S, Chhajed S, Kshirsagar S. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Metformin HCl and Gliclazide, Asian Journal of Pharmaceutical Analysis, 2016; 6(3):151-154
14. Rao VB, Vijetha P, Vidyadhara S, Kavita K. A Novel RP-HPLC Method Development and Validation for the Determination of Pioglitazone and Glimepride in Bulk and Pharmaceutical Formulations, Asian Journal of Pharmaceutical Analysis, 2017; 7(3): 145-150
15. Gadge SS, Nakod DA, Wasnik PV, Gatkine MT, Zile SS, Mohije HN, Salode LV. Development and Validation of Q-absorbance Ratio method for Simultaneous Estimation of Teniligliptin hydrobromide and Metformin HCl in Multicomponent Dosage form, Asian Journal of Pharmaceutical Analysis. 2019; 9(4):215-218
16. Farkade K, Tawar M. Analytical Method Validation and Quantitative Analysis for Active Pharmaceutical Ingredient and Marketed Formulation of Teniligliptin Hydrobromide by UV Spectroscopy, Asian Journal of Pharmaceutical Analysis. 2021; 11(3):195-8
17. More SS, Sonawane SS, Chhajed SS, Kshirsagar JS. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Saxagliptin and Dapagliflozin in Tablets, Asian Journal of Pharmacy and Technology. 2018; 8(3):145-148
18. Harikrishnan N, MuraliKrishna U, Shaik B, Bhavsar V, V Manjusha, Kumar RV. Development and Validation of UV-Spectrophotometric Method of Glibenclamide (Glyburide) in Bulk and Pharmaceutical Formulations, Asian Journal of Research in Chemistry. 2010; 3(2):316-318
19. Fathima H, Havannavar T N, Jahan A. Estimation and validation of Remogliflozin etabonate in dosage form and in bulk drug by spectrophotometric, Asian Journal Research in Chemistry. 2022; 15(2)166-0
20. Venkatesh S, Jyothi S, Chiluka R, Padmavati Y. Development of UV-Spectrophotometric Method for the Simultaneous Estimation of Nateglinide and Piperine in combined tablet dosage form, Asian Journal of Pharmaceutical Analysis. 2020; 10(3):134-140